Compare ADT Inc (ADT) vs Nuvalent Inc (NUVL) Price & Performance

ADT trades at $6.91, up 1.17% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with an 80.82% gross margin and 12.14% net margin, supported by positive news including recent industry awards and board participation in the Connectivity Standards Alliance. Cash flow from operations remains robust at $1.88 billion for 2025, though net cash flow was slightly negative.

Outlook is positive with analyst consensus leaning buy (47% buy ratings), but risks include high long-term debt of $7.51 billion and competitive pressures in home security. Revenue growth is stable, and valuation metrics like P/E of 8.88 suggest potential undervaluation, making it attractive for value-oriented investors mindful of leverage.

Nuvalent (NUVL) trades at $123.72, down slightly by 0.01% on the day, with a price-to-book ratio of 8.34. The stock exhibits a bullish technical trend, supported by strong moving averages, though RSI levels indicate overbought conditions. Recent financials show negative profitability, with a net loss of $425.38 million in 2025 and negative operating cash flow, but the company secured $515.34 million in financing. A major development is the pending $10.6 billion acquisition by GSK at $124 per share, announced in June 2026, which has driven significant investor attention and legal scrutiny over fairness.

The outlook for NUVL is heavily influenced by the GSK acquisition, offering a near-term exit at $124 per share. Risks include ongoing shareholder investigations into the deal's fairness and the company's persistent losses. Analyst sentiment is mixed, with 42% recommending buy and 58% hold, reflecting uncertainty around the acquisition's completion and valuation. Investors should monitor regulatory approvals and any competing offers that may emerge, as these will determine final shareholder returns.